All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Article

December 2, 2010

Genzyme Meets Consent Decree Deadline

Genzyme (Cambridge, MA) officially ended fill?finish operations at its Allston Landing, Massachusetts, plant for products sold in the United States, thereby fulfilling a requirement of a US Food and Drug Administration consent decree.

On Nov. 24, 2010, Genzyme (Cambridge, MA) officially ended fill–finish operations at its Allston Landing, Massachusetts, plant for products sold in the United States, thereby fulfilling a requirement of a US Food and Drug Administration consent decree. Genzyme has transferred all fill–finish activities for its Cerezyme (imiglucerase for injection), Myozyme (alglucosidase alfa), Fabrazyme (agalsidase beta), and Thyrogen (thyrotropin alfa for injection) products for the US market to its Waterford, Ireland, plant and to a third-party contract manufacturer. This change effectively lifts all previous restrictions on the company’s marketing and distribution of Thyrogen within the United States.

The consent decree requires Genzyme to end all remaining fill–finish activities in Allston Landing for products sold outside of the United States by August 31, 2011. Genzyme is cooperating with regulatory authorities to achieve this goal.

During an inspection of the Allston Landing plant from Oct. 8, 2009 to Nov. 13, 2009, FDA inspectors concluded that Genzyme’s systems for ensuring manufacturing quality were inadequate, thus causing production delays, critical shortages of medically necessary products, and contamination. The plant’s manufacturing problems violated FDA’s regulations for good manufacturing practice, according to the agency. The consent decree, which Genzyme signed in May 2010, requires the company to correct manufacturing-quality violations at the plant.

FDA required Genzyme to draft a remediation plan that includes ongoing oversight from Quantic, the company’s third-party consultant. If remediation actions are not complete by certain milestones, Genzyme must pay FDA $15,000 per day per affected drug until the compliance milestones are met. After the remediation plan has been completed, Quantic will oversee Genzyme for five years and submit annual reports to the agency. Genzyme expects that the remediation plan will require approximately two to three years to complete.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
PharmTech Weekly News Roundup
Related Content
Advertisement
Shanghai.China-Jan. 8th 2022: Fosun Pharma company logo on office building at night. A Chinese pharmaceutical company mostly owned by Fosun International | Image Credit: © Robert - stock.adobe.com
August 31st 2025

Fosun Pharma to Exclusively Develop Accro Bioscience Anti-Inflammatory in China

Patrick Lavery
Drug Solutions Podcast: Sustainable Solutions for Biopharma
August 31st 2025

Drug Solutions Podcast: Sustainable Solutions for Biopharma

Patrick Lavery
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 31st 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
August 31st 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 31st 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
August 31st 2025

Nelson Labs Expands Laboratory Capacity and Services at German Facility

Susan Haigney
Related Content
Advertisement
Shanghai.China-Jan. 8th 2022: Fosun Pharma company logo on office building at night. A Chinese pharmaceutical company mostly owned by Fosun International | Image Credit: © Robert - stock.adobe.com
August 31st 2025

Fosun Pharma to Exclusively Develop Accro Bioscience Anti-Inflammatory in China

Patrick Lavery
Drug Solutions Podcast: Sustainable Solutions for Biopharma
August 31st 2025

Drug Solutions Podcast: Sustainable Solutions for Biopharma

Patrick Lavery
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 31st 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
August 31st 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 31st 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
August 31st 2025

Nelson Labs Expands Laboratory Capacity and Services at German Facility

Susan Haigney
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.